Want to see OTSKY full AI Analyst Report?
OTSKY Stock Chart & Stats
$29.69
-$0.33(-1.23%)
At close: 4:00 PM EST
$29.69
-$0.33(-1.23%)
Day’s Range― - ―
52-Week Range$22.13 - $36.80
Previous CloseN/A
Volume11.00K
Average Volume (3M)4.89K
Market Cap
$36.84B
Enterprise Value$5.30T
Total Cash (Recent Filing)$540.63B
Total Debt (Recent Filing)$195.47B
Price to Earnings (P/E)16.3
Beta0.09
Next Earnings
Jul 31, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend Yield1.48%
Share Statistics
EPS (TTM)360.32
Shares Outstanding1,085,977,800
10 Day Avg. Volume2,307
30 Day Avg. Volume4,892
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)1.55
Price to Sales (P/S)1.82
P/FCF Ratio14.23
Enterprise Value/Market Cap143.86
Enterprise Value/Revenue2.08
Enterprise Value/Gross Profit2.90
Enterprise Value/Ebitda9.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.86
Revenue Forecast (FY)$16.20B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and operating margins indicate durable pricing power and efficient cost structure across pharma and consumer segments. This margin profile supports reinvestment in R&D and commercialization, improving resilience to demand shifts over the next several months.
Conservative Balance SheetVery low leverage provides long-term financial flexibility to fund pipeline development, absorb regulatory or reimbursement shocks, and pursue opportunistic M&A without stressing liquidity. This reduces refinancing and solvency risk over a 2–6 month horizon.
Strong Free Cash FlowSubstantial absolute FCF and high FCF-to-net-income coverage underpin the company's ability to self-fund R&D, sustain operations, and support shareholder returns. That cash generation capacity strengthens strategic optionality over the medium term.
Bears Say
Weak Cash ConversionModerate OCF/NI and a slight decline in FCF growth point to working-capital timing or operational cash volatility. Over months this can constrain discretionary spending or amplify funding needs if revenue or margins soften, reducing predictability of cash available for investments.
Growth And Margin VolatilityLarge year-to-year swings in margins and episodic earnings weakness indicate sensitivity to product cycles or one-time items. This volatility complicates forecasting and capital-allocation decisions, increasing execution risk for sustaining returns in the medium term.
Product Lifecycle And Regulatory RiskBusiness relies on successful approvals, label expansions and patent protection. Delays, competition after exclusivity expiry, or unfavorable reimbursement decisions can materially affect revenues and margins, creating structural execution risk across the planning horizon.
Otsuka Holdings Co News
OTSKY FAQ
What was Otsuka Holdings Co Ltd’s price range in the past 12 months?
Otsuka Holdings Co Ltd lowest stock price was $22.13 and its highest was $36.80 in the past 12 months.
What is Otsuka Holdings Co Ltd’s market cap?
Otsuka Holdings Co Ltd’s market cap is $36.84B.
When is Otsuka Holdings Co Ltd’s upcoming earnings report date?
Otsuka Holdings Co Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 25 days.
How were Otsuka Holdings Co Ltd’s earnings last quarter?
Otsuka Holdings Co Ltd released its earnings results on Apr 28, 2026. The company reported $0.583 earnings per share for the quarter, beating the consensus estimate of $0.431 by $0.152.
Is Otsuka Holdings Co Ltd overvalued?
According to Wall Street analysts Otsuka Holdings Co Ltd’s price is currently Overvalued.
Does Otsuka Holdings Co Ltd pay dividends?
Otsuka Holdings Co Ltd pays a Semiannually dividend of $0.217 which represents an annual dividend yield of 1.48%. See more information on Otsuka Holdings Co Ltd dividends here
What is Otsuka Holdings Co Ltd’s EPS estimate?
Otsuka Holdings Co Ltd’s EPS estimate is 0.48.
How many shares outstanding does Otsuka Holdings Co Ltd have?
Otsuka Holdings Co Ltd has 1,085,977,800 shares outstanding.
What happened to Otsuka Holdings Co Ltd’s price movement after its last earnings report?
Otsuka Holdings Co Ltd reported an EPS of $0.583 in its last earnings report, beating expectations of $0.431. Following the earnings report the stock price went up 4.703%.
Which hedge fund is a major shareholder of Otsuka Holdings Co Ltd?
Currently, no hedge funds are holding shares in OTSKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Otsuka Holdings Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.37%
12-Months-Change
Fundamentals
Return on Equity
12.85%
Trailing 12-Months
Asset Growth
7.13%
Trailing 12-Months
Company Description
Otsuka Holdings Co Ltd
Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded on July 8, 2008 and is headquartered in Tokyo, Japan.
OTSKY Company Deck
OTSKY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong overall performance in both pharmaceutical and nutraceutical segments with significant revenue and profit growth, and positive strategic expansions such as the acquisition for drug discovery. However, there were challenges such as impairment losses and increased SG&A expenses.View all OTSKY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.28% Other Institutional Investors
99.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---